PremiumCompany AnnouncementsAstraZeneca Advances Early Combo Drug Study With Fresh Clinical Update1d agoAZN
PremiumRatingsAstraZeneca: Breast Cancer Pipeline Strength Supports Buy Rating as Sachin Jain Reiterates Unchanged 16,500 GBp Price Target1d agoAZN
AstraZeneca: Breast Cancer Pipeline Strength Supports Buy Rating as Sachin Jain Reiterates Unchanged 16,500 GBp Price Target